Liquid biopsies are a promising tool for molecular tumor profiling and monitoring (Siravegna et al., 2017). One of their main advantages over solid biopsies is that they can detect intratumoral heterogeneity, which is unappreciated by single-site tissue biopsies. However, we are still at the beginning of their incorporation into routine oncology practice.